We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Intranasal administration of a virus like particles‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern.
- Authors
Rothen, Dominik A.; Krenger, Pascal S.; Nonic, Aleksandra; Balke, Ina; Vogt, Anne‐Cathrine S.; Chang, Xinyue; Manenti, Alessandro; Vedovi, Fabio; Resevica, Gunta; Walton, Senta M.; Zeltins, Andris; Montomoli, Emanuele; Vogel, Monique; Bachmann, Martin F.; Mohsen, Mona O.
- Abstract
Background: The highly contagious SARS‐CoV‐2 is mainly transmitted by respiratory droplets and aerosols. Consequently, people are required to wear masks and maintain a social distance to avoid spreading of the virus. Despite the success of the commercially available vaccines, the virus is still uncontained globally. Given the tropism of SARS‐CoV‐2, a mucosal immune reaction would help to reduce viral shedding and transmission locally. Only seven out of hundreds of ongoing clinical trials are testing the intranasal delivery of a vaccine against COVID‐19. Methods: In the current study, we evaluated the immunogenicity of a traditional vaccine platform based on virus‐like particles (VLPs) displaying RBD of SARS‐CoV‐2 for intranasal administration in a murine model. The candidate vaccine platform, CuMVTT‐RBD, has been optimized to incorporate a universal T helper cell epitope derived from tetanus‐toxin and is self‐adjuvanted with TLR7/8 ligands. Results: CuMVTT‐RBD vaccine elicited a strong systemic RBD‐ and spike‐IgG and IgA antibodies of high avidity. Local immune response was assessed, and our results demonstrate a strong mucosal antibody and plasma cell production in lung tissue. Furthermore, the induced systemic antibodies could efficiently recognize and neutralize different variants of concern (VOCs). Conclusion: Our data demonstrate that intranasal administration of CuMVTT‐RBD induces a protective systemic and local specific antibody response against SARS‐CoV‐2 and its VOCs.
- Subjects
INTRANASAL administration; SARS-CoV-2; T helper cells; VIRUS-like particles; IMMUNOGLOBULINS
- Publication
Allergy, 2022, Vol 77, Issue 8, p2446
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15311